HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Rad30 protein

Subscribe to New Research on Rad30 protein

homologous to DinB protein from E. coli; amino acid sequence in first source; GenBank Q47155 (Rad30); AB024313 (XPV); RefSeq NM_006502 (human), NM_030715 (mouse)

Also Known As:

DNA polymerase eta; DNA polymerase p.2018; POLH protein; POLH protein, human; Polh protein, mouse; RAD30A; RAD30A protein, human; Rad30A protein, mouse; XP-V protein; XP-V protein, human; XPV protein; poleta; polymerase (DNA directed), eta (RAD 30 related) protein, mouse; polymerase (DNA directed), eta protein, human

Networked: 83 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Enzymes and Coenzymes
- Enzymes: 34502
  - Transferases: 4296
    - Phosphotransferases: 30637
      - Nucleotidyltransferases: 1
        DNA Nucleotidyltransferases: 4
        DNA-Directed DNA Polymerase: 269
        Rad30 protein: 83

Experts

1.	Hanaoka, Fumio: 13 articles (06/2010 - 01/2002)
2.	Masutani, Chikahide: 12 articles (06/2010 - 01/2002)
3.	Lehmann, Alan R: 10 articles (06/2010 - 01/2002)
4.	Prakash, L: 8 articles (11/2001 - 08/2000)
5.	Prakash, S: 8 articles (11/2001 - 08/2000)
6.	Kannouche, Patricia: 7 articles (08/2006 - 11/2002)
7.	Johnson, R E: 6 articles (11/2001 - 08/2000)
8.	Hanaoka, F: 6 articles (01/2001 - 06/2000)
9.	Stary, Anne: 5 articles (08/2006 - 01/2002)
10.	Sarasin, Alain: 5 articles (08/2006 - 01/2002)

Related Diseases

1.	Xeroderma Pigmentosum (Kaposi's Disease) 10/01/2011 - "Xeroderma pigmentosum variant: complementary molecular approaches to detect a 13 base pair deletion in the DNA polymerase eta gene." 04/01/2008 - "Mutations in the poleta gene are responsible for the genetic defect in xeroderma pigmentosum variant patients. " 12/01/2007 - "Xeroderma pigmentosum variant (XP-V) cells lack the damage-specific DNA polymerase eta and have normal excision repair but show defective DNA replication after UV irradiation. " 04/01/2007 - "In the absence of active poleta in xeroderma pigmentosum variant (XPV) patients, mutations accumulate at sites of UV-induced DNA damage, providing the initiating step in skin carcinogenesis. " 02/01/2006 - "DNA polymerase eta, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates the DNA damage checkpoint and p53 activation."
2.	Neoplasms (Cancer) 09/28/2000 - "The XPV gene encodes DNA polymerase eta, which catalyzes an accurate translesion synthesis, indicating that the XPV gene contributes tumor suppression in normal individuals. " 11/01/2000 - "Inactivation of Poleta could afford a useful strategy for enhancing the effectiveness of these agents in cancer chemotherapy." 05/01/2009 - "Defects in the gene encoding human Poleta result in xeroderma pigmentosum variant (XP-V), an inherited cancer-prone syndrome. " 03/02/2007 - "Saccharomyces cerevisiae Rad30 is the homolog of human DNA polymerase eta whose inactivation leads to the cancer-prone syndrome xeroderma pigmentosum variant. " 01/19/2004 - "It has been proposed, based on the V gene mutation pattern of patients with the cancer-prone xeroderma pigmentosum variant (XP-V) syndrome who are deficient in DNA polymerase eta (pol eta), that this enzyme could be responsible for a large part of the mutations occurring on A/T bases. "
3.	Skin Neoplasms (Skin Cancer) 06/24/2010 - "Structural basis for the suppression of skin cancers by DNA polymerase eta." 11/01/2006 - "Here, we tested the hypothesis that somatic mutations and/or polymorphisms in the POLH gene that encodes Poleta are associated with the induction of UV-dependent skin cancers. " 01/01/2001 - "Thus, by preventing UV mutagenesis at a wide spectrum of dipyrimidine sites, Poleta plays a pivotal role in minimizing the incidence of sunlight-induced skin cancers in humans." 10/01/2011 - "Deficiencies of DNA polymerase eta-an enzyme mediating replication past UV-induced DNA damage-predispose individuals to xeroderma pigmentosum variant (XPV) and result in a high incidence of skin cancers. " 02/01/2010 - "DNA polymerase eta (PolH), a Y family translesion polymerase, is required for repairing UV-induced DNA damage, and loss of PolH is responsible for early onset of malignant skin cancers in patients with xeroderma pigmentosum variant (XPV), an autosomal recessive disorder. "
4.	Carcinoma (Carcinomatosis) 05/01/2011 - "The expression of genes involved in DNA repair pathways (PARP1, ERCC1, XPA, XPF, XPG, BRCA1, FANCA, FANCC, FANCD2, FANCF and PolEta), and in DNA damage transduction (Chk1 and Claspin) was measured by RT-PCR in 13 stage I borderline and 77 stage I and 88 III ovarian carcinomas. " 12/26/2003 - "We investigated the fidelity of HPV 16 E1- and E2-mediated DNA replication of non-damaged and UVC-damaged templates in a variety of cell lines with different genetic backgrounds; C33a (derived from an HPV-negative cervical carcinoma), XP30RO (deficient in the by-pass polymerase eta (poleta)), XP30eta (expressing a restored wild-type poleta), XP12RO (nucleotide excision repair defective), and MRC5 (derived from a 14-week-old human fetus). " 11/01/2006 - "We sequenced the exonic regions of the Poleta open reading frame in DNA from 17 paired samples of squamous cell skin carcinoma and adjacent histologically normal tissue. "
5.	Genomic Instability 08/01/2014 - "DNA polymerase eta (Pol η) is one of several Y family trans-lesion synthesis (TLS) polymerases in humans and plays an important role in maintaining genome stability after ultraviolet (UV) irradiation, as it carries out error-free TLS at sites of UV-induced lesions. " 10/17/2012 - "DNA polymerase eta (Polη), the product of the xeroderma pigmentosum variant gene, is required for translesion DNA synthesis, and plays a pivotal role in preventing genome instability after DNA damage induced by genotoxic agents. "

Related Drugs and Biologics

1.	Rad30 protein
2.	DNA (Deoxyribonucleic Acid)
3.	Pyrimidine Dimers
4.	DNA-Directed DNA Polymerase (Polymerases, DNA)
5.	Thymine
6.	Platinum
7.	Cisplatin (Platino)
8.	DNA Adducts
9.	DNA polymerase iota
10.	Replication Protein C (Replication Factor C)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)